GermanyGermany

Infectious alliance between diagnostic behemoths Siemens and Illumina

04.11.2011

Munich/San Diego – New challenges breed new alliances. Siemens Healthcare, the health-tech subsidiary of the German technology giant, and Next-Generation sequencing world market leader Illumina, want to make rules for using next-generation sequencing in rapid disease identification. As a first concrete step, the partners want to tweak Siemens' molecular HIV tests so that they are compatible with Illumina's new NGS desktop sequencer MiSeq. If this works, the two companies want to present more sequencing-based infectious disease assays for the clinical diagnostics market."Next-generation sequencing is a transformational technology that we believe will significantly impact clinical diagnostics over the next five years," said Michael Reitermann, CEO, Siemens Healthcare Diagnostics. The new partnership aims to set first standards for this new business segment, Reitermann said. For 10 years now Siemens has a DNA sequencing-based assay on offer which can test for resistance in HIV. The Trugene HIV-1 Genotyping Assay was the first such kit to for HIV to be cleared by the FDA.

Germany, FranceGermany

21.12.2011

Martinsried/Paris - Sanofi has done some Christmas shopping in Munich and has licensed Scil Technology’s programme for the regenerative treatment of osteoarthritis and cartilage disorders. Under the agreement, Scil could reap up...

GermanyGermany

20.12.2011

Monheim - It's nearly Christmas, and Bayer Crop Science gives out some presents. As the company announced, a $750 million settlement with U.S. rice farmers is now binding and can move forward. In summer the German firm had agreed...

GermanyGermany

16.12.2011

Bonn – Germany’s federal government is prolonging one of its most successful measures to date for stimulating the establishment of high-tech companies – the High-Tech-Gründerfonds (HTGF). The HTGF was launched in 2005 with €272m...

GermanyGermany

15.12.2011

Leverkusen – One short statement from the European Medicines Agency (EMA) means one giant step for German biotech company Biofrontera. The agency issued a favourable opinion on the firm’s marketing approval application for its...

GermanyGermany

15.12.2011

While the European sovereign debt crisis keeps capital markets in a choke-hold, with potential negative effects on the financing situation in many industries – including biotech – there was encouraging news for drug-developing...

GermanyGermany

08.12.2011

Heidelberg – There is still life in the European life science finance. EMBL Ventures has closed a €40m fund. The early stage investor and the venture capital arm of the European Molecular Biology Laboratory(EMBL) announced the...

GermanyGermany

03.11.2011

Düsseldorf – BIO-Europe 2011 in Düsseldorf has again broken all previous records in terms of participants and company numbers. More than 3,000 representatives from 1,800 companies registered for Europe‘s largest partnering event....

GermanyGermany

02.11.2011

Brussels/San Francisco – As the biggest biotech partnering event on the continent, BioEurope, draws to a close, the venture capital community sent ambivalent messages for life sciences. Dow Jones VentureSource, an analyst,...

GermanyGermany

27.10.2011

Leverkusen - Bayer Pharma has a lucky streak. The pharma division of the German chemical giant announced positive Phase III results from regorafenib in colorectal cancer. “We are extremely encouraged by the result of this...

Displaying results 11 to 20 out of 454

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-germany/browse/1/article/infectious-alliance-between-diagnostic-behemoths-siemens-and-illumina.html

Print Magazine

Product of the week

Products

Events

All Events

Current issue

All issues